DexCom, Inc. (DXCM) Earnings Call Transcripts

DexCom, Inc.'s Latest Earnings Call - September 9, 2026

In the Q3 2026 earnings call, DexCom, Inc. (DXCM) reported strong performance driven by growth in its type 2 non-insulin market and ongoing advancements in its product offerings. The company maintained its full-year guidance, expecting revenue growth of 10% or more, with a patient base growing in the high teens. Management expressed confidence in upcoming Medicare coverage proposals and highlighted the positive reception of its 15-day G7 product, which is expected to drive future revenue growth.

Reported metrics

Guidance from management

DexCom maintained its full-year revenue growth guidance of 10% or more, with expectations for continued patient base growth and the successful rollout of the 15-day G7 product. Management indicated that the impact of the Ireland facility would be a headwind initially but expects significant contributions from the 15-day product in the future.

What management said

Yes. So we're still in that same window timing. There's a lot of back and forth that continues to go on, has and continues to go on. And still feel very confident in the timing that we released and still would expect it over that period. And as you know, in our LRP, we have it starting about 6 months after the end of this year. So kind of midpoint of next year is our assumption. Those are all still ring true and thin...

We haven't seen anything to date. We've been very happy with it. And I say the roll down has gone well. So certainly happy to have seen it. There's always the potential for 1Z, 2Z out there, but I wouldn't say this, what we've seen is nothing significant, which is great.

What analysts pressed on

Analysts expressed concerns over the stagnant revenue growth of the Stelo product, questioning what specific enhancements would drive adoption. Additionally, there were inquiries about the potential operational challenges associated with the new Ireland facility and its impact on margins in the short term.

Main topics on the call

• Type 2 Non-Insulin Market Expansion — DexCom is optimistic about its type 2 non-insulin market, with management stating, "Once you have CMS cover... you now have 75% coverage," which is expected to significantly increase patient access and utilization. The c...
• Medicare Coverage Proposal Timeline — Management reiterated confidence in the timing of the Medicare coverage proposal, stating, "we still would expect it over that period" and that they are actively building capabilities in anticipation of this coverage. Th...
• 15-Day G7 Product Performance — The 15-day G7 product has received positive feedback, with management targeting "approaching 50% of our U.S. G-Series population moved over" by year-end. This product is expected to enhance gross margins significantly as...
• Global Patient Base Growth — DexCom reported that its patient base is expected to grow in the high teens, which is consistent with previous guidance. Management noted, "the base has gotten bigger, and so the percentages change a bit," indicating sta...

Read the full DexCom, Inc. transcript (September 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 75 DexCom, Inc. earnings call transcripts on record, spanning January 13, 2020 to September 9, 2026. Based on this history, DexCom, Inc. reports quarterly. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DXCM

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

75

First call

January 13, 2020

Most recent

September 9, 2026

Reporting cadence

quarterly